For the first time, China will become the first country to research and develop 1.1 new drugs in the world!

Recently, "2016 Beijing international medical engineering transformation Summit Forum" was held in Zhongguancun medical engineering transformation center in Beijing to promote collaborative innovation of key links in the field of medicine The summit forum was co sponsored by China food and drug enterprise quality and Safety Promotion Association, Zhongguancun medical engineering transformation center and University of Pennsylvania Medical transformation center Academician of Chinese Academy of engineering, sang Guowei, served as the Chinese chairman, academician of American Academy of Sciences, Professor MIT, and academician Harvey F Lodish, served as the foreign chairman Jiao Hong, deputy director of the State Food and drug administration, Yu Wenming, deputy director of the State Administration of traditional Chinese medicine, and Cong Luoluo, director of the Beijing food and Drug Administration attended the meeting and delivered speeches In recent years, innovative policies and measures in the field of medicine have been introduced frequently at the national level, which makes it feasible for innovative drugs to be listed first in the Chinese market from the policy level With the help of in-depth research of cutting-edge science, scientists have really solved the problems from basic to clinical, which is the theme and direction of discussion advocated by this summit forum As a guest of the summit, Professor Chen Xiangmei, academician of Chinese Academy of engineering and chairman of Chinese society of Nephrology, was specially appointed as a scientist consultant of Zhongguancun medical engineering transformation center in China At the same time, she also put forward the view that "the essence of translational medicine is the combination of theory and practice, which is the integration of foundation and clinic" in the main forum In view of the current research hotspot of chronic kidney disease (CKD), taking the most common complication renal anemia as an example, she deeply analyzed the current treatment status and development trend of renal anemia, and shared the latest research progress in the world 。 The world's first hypoxia inducible factor prolyl hydroxylase inhibitor (hif-phi) for the treatment of renal anemia has been strictly standardized in phase I and phase II clinical trials in China She disclosed that the innovative drug is currently undergoing phase III clinical trials in China, and its progress has been ahead of other countries such as Europe and the United States, which makes the oral new drug expected to become the first global R & D and the first class 1.1 new drug to be listed in China Chronic kidney disease has become an important public health problem in China Chronic kidney disease has the characteristics of complex etiology, hidden symptoms and high incidence rate, accompanied by anemia, hypertension and other complications The prevalence of CKD in China is 10.8% of the adult population, and the number of patients is about 120 million, among which the number of patients with end-stage renal disease is 1-2 million, and the number of patients eligible for dialysis treatment is only about 400000 The reason is that many patients can not get dialysis treatment due to economic pressure, so academician Chen also strongly called on the relevant departments of medical insurance to give more attention and support to patients with end-stage renal disease, so that they can receive dialysis treatment and their lives can be continued Renal anemia is the invisible killer of chronic kidney disease As one of the most important complications of chronic kidney disease patients, with the decrease of renal function, the incidence of anemia is gradually increased, and the degree is also gradually increased 98.2% of dialysis patients are combined with anemia, 52.1% of non dialysis patients are combined with poor blood, which is an important reason for the high mortality of CKD patients According to the data of Chinese national hemodialysis data system (cnrds) over the years, at present, the standard rate of renal anemia treatment in China is relatively low Renal anemia can not only lead to physical exhaustion and other symptoms leading to the decline of quality of life, but also increase the risk of cardiovascular and cerebrovascular disease and mortality The anemia of diabetic nephropathy patients appeared earlier and more serious, the changes of cardiovascular and cerebrovascular diseases were serious, the mortality was higher, and the response to drug treatment to correct anemia was also poor In addition, renal anemia may also accelerate the progress of renal disease and increase the risk of dialysis Therefore, if renal anemia is not treated in time, it will not only increase the economic burden of patients, but also increase the national health insurance expenditure At present, the mainstream treatment plans in China include injection of erythropoietin (hereinafter referred to as "erythropoietin") and iron, which have many limitations Therefore, academician Chen said in his speech that he is very looking forward to an innovative drug for the treatment of renal anemia to improve the current situation Innovation enables Chinese patients to enjoy the most cutting-edge scientific and technological achievements in the world for the first time In recent years, precision treatment has become the development trend of the medical industry At this meeting, academician Chen was the first to initiate the original research, the first to set a precedent, and the first to launch a new oral drug for the treatment of renal anemia in China, which is an example of precise treatment Compared with the injection of erythropoietin, it can not only effectively improve the hemoglobin level, but also safely tolerate Therefore, the new drug has been recognized by the State Food and drug administration as a class 1.1 new drug, enjoying the relevant rapid review and approval policies of national innovative drugs It is expected that China will be the first listed country, even earlier than the United States and other developed countries, and Chinese patients will enjoy the most cutting-edge scientific and technological achievements in the world For a long time, academician Chen Xiangmei has paid close attention to the living conditions of uremic patients and is committed to improving the current situation of chronic kidney disease treatment in China She called at the conference that "if the complications of uremia, such as renal anemia, are properly controlled, it can effectively improve the prognosis of the disease, reduce the hospitalization rate, and greatly improve the quality of life of patients Therefore, it is hoped that relevant departments will give more attention and support to patients, so that innovative drugs such as hypoxia inducible factor prolyl hydroxylase inhibitor (hif-phi) can be put on the market as soon as possible, be applied in clinical practice and enter the medical insurance, and finally make patients get timely and effective treatment "